Treatment of chronic hepatitis C in patients who failed interferon monotherapy: Effects of higher doses of interferon and ribavirin combination therapy

American Journal of Gastroenterology

Volumn 95, Issue 10, 2000, Pages 2928-2935

  Shiffman, Mitchell L ^a,b,c,d   Hofmann, Charlotte M ^a,b,c,d   Gabbay, Joubin ^a,b,c,d   Luketic, Velimir A ^a,b,c,d   Sterling, Richard K ^a,b,c,d   Sanyal, Arun J ^a,b,c,d   Contos, Melissa J ^a,b,c,d   Ryan, Michael J ^a,b,c,d   Yoshida, Cynthia ^a,b,c,d   Rustgi, Vinod ^a,b,c,d  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Eastern Virginia School of Medicine   (United States)

^d INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN;

ADULT; ANTIBODY TITER; ARTICLE; CHRONIC HEPATITIS; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL;

ADULT; ANTIVIRAL AGENTS; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMAN; INTERFERON ALFA-2A; MALE; MIDDLE AGE; RIBAVIRIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TREATMENT FAILURE;

EID: 0033791802     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)01113-8     Document Type: Article

References (29)

1. Long term efficacy of ribavirin plus interferon α in the treatment of chronic hepatitis C
2. Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish study group
3. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
4. Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
5. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
6. Interferon-α-2b, and ribavirin in combination for chronic hepatitis C patients not responding to interferon-α alone. An Italian, multicenter, randomized, controlled, clinical study
7. Interferon-α plus ribavirin in chronic hepatitis C resistant to previous interferon-α course: Results of a randomized multicenter trial
8. Long term re-treatment with interferon and ribavirin combination therapy in patients with chronic hepatitis C who are non-responders to interferon alone: A preliminary study
9. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: A randomized trial
10. A randomized trial of ribavirin and interferon-alpha vs interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment
11. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C
12. A controlled study to determine the optimal dose regimen of interferon-α 2b in chronic hepatitis C
13. Lack of benefit of escelating dosage of interferon alpha in patients with chronic hepatitis C
14. Response to higher doses of interferon alpha-2b in patients with chronic hepatitis C: A randomized multicenter trial
15. Role of high dose interferon in the treatment of chronic hepatitis C
16. Therapy of hepatitis C: Overview
17. Prediction of response during interferon alpha 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
18. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay
19. Formulation and application of numerical scoring system for assessing histologic activity in asymptomatic chronic hepatitis
20. Better efficacy of a 12 month interferon alpha-2b retreatment in patients with chronic hepatitis C relapsing after 6 month treatment: A multicenter, controlled, randomized trial
21. Raising the dose of interferon does not improve the response in chronic hepatitis C
22. High-dose interferon α2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A randomized controlled trial
23. Dose increase auguments response rate to interferon-α in chronic hepatitis C
24. Treatment of chronic hepatitis C with escelating doses of interferon-α-2b increases both biochemical and virological response
25. Re-treatment of chronic hepatitis C with consensus interferon
26. A pilot study of combination therapy with ribavirin plus interferon alpha for interferon alpha-resistant chronic hepatitis C
27. A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis
28. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose
29. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group